share_log
Breakings ·  Dec 20 22:13
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for Vgt-1849a, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment